Mark Guttman

11.8k total citations · 1 hit paper
107 papers, 6.7k citations indexed

About

Mark Guttman is a scholar working on Neurology, Cellular and Molecular Neuroscience and Molecular Biology. According to data from OpenAlex, Mark Guttman has authored 107 papers receiving a total of 6.7k indexed citations (citations by other indexed papers that have themselves been cited), including 68 papers in Neurology, 61 papers in Cellular and Molecular Neuroscience and 16 papers in Molecular Biology. Recurrent topics in Mark Guttman's work include Neurological disorders and treatments (51 papers), Parkinson's Disease Mechanisms and Treatments (45 papers) and Genetic Neurodegenerative Diseases (37 papers). Mark Guttman is often cited by papers focused on Neurological disorders and treatments (51 papers), Parkinson's Disease Mechanisms and Treatments (45 papers) and Genetic Neurodegenerative Diseases (37 papers). Mark Guttman collaborates with scholars based in Canada, United States and United Kingdom. Mark Guttman's co-authors include Stephen J. Kish, Yoshiaki Furukawa, Junchao Tong, Jane S. Paulsen, Oleh Hornykiewicz, Sylvain Houle, Isabelle Boileau, Michael R. Hayden, Gabriel C. Léger and Julie C. Stout and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Clinical Investigation.

In The Last Decade

Mark Guttman

106 papers receiving 6.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Detection of Huntington's disease decades before diagnosis: the Predict-HD study

2007 605 citations Jane S. Paulsen, Douglas R. Langbehn et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark Guttman Canada	47	4.3k	3.5k	1.5k	562	518	107	6.7k
Ali H. Rajput Canada	49	6.0k 1.4×	3.5k 1.0×	1.4k 0.9×	551 1.0×	932 1.8×	124	8.2k
Ray L. Watts United States	42	4.3k 1.0×	2.1k 0.6×	974 0.7×	942 1.7×	747 1.4×	84	6.0k
Bernard Ravina United States	38	4.9k 1.1×	2.1k 0.6×	1.6k 1.1×	903 1.6×	612 1.2×	84	7.3k
Peter A. LeWitt United States	48	5.0k 1.2×	2.1k 0.6×	1.2k 0.8×	809 1.4×	755 1.5×	200	8.1k
G. Frederick Wooten United States	42	2.1k 0.5×	2.8k 0.8×	1.6k 1.1×	689 1.2×	402 0.8×	108	5.9k
Marios Politis United Kingdom	39	3.1k 0.7×	1.7k 0.5×	1.0k 0.7×	910 1.6×	707 1.4×	99	5.5k
Roberto Ceravolo Italy	49	4.3k 1.0×	1.8k 0.5×	1.1k 0.7×	716 1.3×	730 1.4×	275	8.2k
H. Przuntek Germany	50	4.6k 1.1×	3.3k 0.9×	2.2k 1.5×	1.4k 2.5×	1.2k 2.3×	279	9.0k
Manfred Gerlach Germany	44	2.6k 0.6×	2.0k 0.6×	1.7k 1.2×	595 1.1×	1.1k 2.1×	174	6.7k
M. Gerlach Germany	40	2.3k 0.5×	1.8k 0.5×	1.4k 0.9×	426 0.8×	766 1.5×	122	5.7k

Countries citing papers authored by Mark Guttman

Since Specialization

Citations

This map shows the geographic impact of Mark Guttman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Guttman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Guttman more than expected).

Fields of papers citing papers by Mark Guttman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Guttman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Guttman. The network helps show where Mark Guttman may publish in the future.

Co-authorship network of co-authors of Mark Guttman

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Guttman. A scholar is included among the top collaborators of Mark Guttman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Guttman. Mark Guttman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Guttman, Mark, et al.. (2024). Atypical Presentations of Huntington Disease‐like 2 in South African Individuals. Movement Disorders Clinical Practice. 11(7). 850–854.

Guttman, Mark, et al.. (2021). The Impact of Upcoming Treatments in Huntington’s Disease: Resource Capacity Limitations and Access to Care Implications. Journal of Huntington s Disease. 10(2). 303–311. 2 indexed citations

Hassan, Anhar, E. Ray Dorsey, Christopher G. Goetz, et al.. (2018). Telemedicine Use for Movement Disorders: A Global Survey. Telemedicine Journal and e-Health. 24(12). 979–992. 23 indexed citations

Frich, Jan C., D. O. Rae, Richard Roxburgh, et al.. (2016). Health Care Delivery Practices in Huntington’s Disease Specialty Clinics: An International Survey. Journal of Huntington s Disease. 5(2). 207–213. 27 indexed citations

Holtbernd, Florian, Chris C. Tang, Andrew Feigin, et al.. (2016). Longitudinal Changes in the Motor Learning-Related Brain Activation Response in Presymptomatic Huntington's Disease. PLoS ONE. 11(5). e0154742–e0154742. 7 indexed citations

Tong, Junchao, Lee-Cyn Ang, Belinda Williams, et al.. (2015). Low levels of astroglial markers in Parkinson’s disease: relationship to α-synuclein accumulation. Neurobiology of Disease. 82. 243–253. 86 indexed citations

Butt, Debra A., Karen Tu, Jacqueline Young, et al.. (2014). A Validation Study of Administrative Data Algorithms to Identify Patients with Parkinsonism with Prevalence and Incidence Trends. Neuroepidemiology. 43(1). 28–37. 67 indexed citations

Tang, Chris C., Andrew Feigin, Yilong Ma, et al.. (2013). Metabolic network as a progression biomarker of premanifest Huntington’s disease. Journal of Clinical Investigation. 123(9). 4076–4088. 86 indexed citations

Boileau, Isabelle, Pablo Rusjan, Sylvain Houle, et al.. (2008). Increased Vesicular Monoamine Transporter Binding during Early Abstinence In Human Methamphetamine Users: Is VMAT2 a Stable Dopamine Neuron Biomarker?. Journal of Neuroscience. 28(39). 9850–9856. 73 indexed citations

10.

Solomon, Andrea C., Julie C. Stout, Hans J. Johnson, et al.. (2007). Verbal episodic memory declines prior to diagnosis in Huntington's disease. Neuropsychologia. 45(8). 1767–1776. 101 indexed citations

11.

Kish, Stephen J., Junchao Tong, Oleh Hornykiewicz, et al.. (2007). Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. Brain. 131(Pt 1). 120–31. 303 indexed citations

12.

Guttman, Mark, Isabelle Boileau, Jerry J. Warsh, et al.. (2007). Brain serotonin transporter binding in non‐depressed patients with Parkinson's disease. European Journal of Neurology. 14(5). 523–528. 146 indexed citations

13.

Guttman, Mark, et al.. (2002). Parkinsonism in Ontario: Physician Utilization. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 29(3). 221–226. 17 indexed citations

14.

Kish, Stephen J., Íscia Lopes‐Cendes, Mark Guttman, et al.. (1998). Brain Glyceraldehyde-3-Phosphate Dehydrogenase Activity in Human Trinucleotide Repeat Disorders. Archives of Neurology. 55(10). 1299–1299. 45 indexed citations

15.

Hauser, R., Theresa A. Zesiewicz, Stewart A. Factor, Mark Guttman, & William J. Weiner. (1997). Clinical trials of add-on medications in Parkinson's disease: Efficacy versus usefulness. Parkinsonism & Related Disorders. 3(1). 1–6. 3 indexed citations

16.

Gjedde, Albert, Gabriel C. Léger, Paul Cumming, et al.. (1993). Striatal L‐DOPA Decarboxylase Activity in Parkinson's Disease In Vivo: Implications for the Regulation of Dopamine Synthesis. Journal of Neurochemistry. 61(4). 1538–1541. 64 indexed citations

17.

Guttman, Mark, Gabriel C. Léger, Jesse M. Cedarbaum, et al.. (1992). 3‐O‐methyldopa administration does not alter fluorodopa transport into the brain. Annals of Neurology. 31(6). 638–643. 34 indexed citations

18.

Guttman, Mark, Richard S. Burns, W. R. Wayne Martin, et al.. (1989). PET Studies of Parkinsonian Patients Treated with Autologous Adrenal Implants. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 16(3). 305–309. 18 indexed citations

19.

Guttman, Mark, V. Wee Yong, S. U. Kim, et al.. (1988). Asymptomatic striatal dopamine depletion: PET scans in unilateral MPTP monkeys. Synapse. 2(5). 469–473. 33 indexed citations

20.

Guttman, Mark. (1987). Receptors in the Basal Ganglia. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 14(S3). 395–401. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact